Key facts
- This page summarizes John Thomas Burns's Form 4 filing for SELLAS Life Sciences Group, Inc. (SLS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Feb 2023, 16:17.
John Thomas Burns - 02 Feb 2023 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2023, 16:17:32 UTC
- Prior SEC filing
- 05 Dec 2022
- Next SEC filing
- 08 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Burns
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
John Thomas Burns filed Form 4 for SELLAS Life Sciences Group, Inc. (SLS) on 03 Feb 2023.
Change
- Previous filing in this sequence was filed on 05 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- +68%
- Price
- $0.000000
- Shares after
- 49,347
- Date
- 02 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLS
transaction
Derivative
Stock Option Right to Buy)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 02 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $3.34
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person received an award of 20,000 restricted stock units on February 2, 2023, which shall vest as follows: (i) 25% on December 1, 2023 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
Footnote F2
One-quarter (1/4) of the option shares will vest and became exercisable one year from the February 2, 2023 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.